Evidence map›Paper›PMID 39422475›Full record

ArticleProtein science : a publication of the Protein Society2024

On the humanization of VHHs: Prospective case studies, experimental and computational characterization of structural determinants for functionality.

Monica L Fernández-Quintero, Enrico Guarnera, Djordje Musil, Lukas Pekar, Carolin Sellmann, Filipe Freire, Raquel L Sousa, Sandra P Santos, Micael C Freitas, Tiago M Bandeiras and 6 more

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Optimization of synthetic human VProtein science : a publication of the Protein Society · 2025
    Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Monica L Fernández-QuinteroDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.ORCID 0000-0002-6811-6283
Enrico GuarneraAntibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.
Djordje MusilStructural Biology and Biophysics, Merck Healthcare KGaA, Darmstadt, Germany.
Lukas PekarAntibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.
Carolin SellmannAntibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.
Filipe FreireiBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
Raquel L SousaiBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
Sandra P SantosiBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
Micael C FreitasiBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
Tiago M BandeirasiBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
Margarida M S SilvaiBET, Instituto de Biologia Experimental e Tecnológica, Oeiras, Portugal.
Johannes R LoefflerDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.
Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.
Julia HarwardtAntibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.
Stefan ZielonkaAntibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.ORCID 0000-0002-4649-2843
Andreas EversAntibody Discovery and Protein Engineering, Merck Healthcare KGaA, Darmstadt, Germany.ORCID 0000-0003-4643-1941

Funding

iNOVA4Health LA/P/0087/2020iNOVA4Health UIDB/04462/2020iNOVA4Health UIDP/04462/2020the Associate Laboratory LS4FUTURE
6 · The paper itself

Abstract

The humanization of camelid-derived variable domain heavy chain antibodies (VHHs) poses challenges including immunogenicity, stability, and potential reduction of affinity. Critical to this process are complementarity-determining regions (CDRs), Vernier and Hallmark residues, shaping the three-dimensional fold and influencing VHH structure and function. Additionally, the presence of non-canonical disulfide bonds further contributes to conformational stability and antigen binding. In this study, we systematically humanized two camelid-derived VHHs targeting the natural cytotoxicity receptor NKp30. Key structural positions in Vernier and Hallmark regions were exchanged with residues from the most similar human germline sequences. The resulting variants were characterized for binding affinities, yield, and purity. Structural binding modes were elucidated through crystal structure determination and AlphaFold2 predictions, providing insights into differences in binding affinity. Comparative structural and molecular dynamics characterizations of selected variants were performed to rationalize their functional properties and elucidate the role of specific sequence motifs in antigen binding. Furthermore, systematic analyses of next-generation sequencing (NGS) and Protein Data Bank (PDB) data was conducted, shedding light on the functional significance of Hallmark motifs and non-canonical disulfide bonds in VHHs in general. Overall, this study provides valuable insights into the structural determinants governing the functional properties of VHHs, offering a roadmap for their rational design, humanization, and optimization for therapeutic applications.

Indexed as

Immunoglobulin Heavy ChainsAmino Acid SequenceAnimalsComplementarity Determining RegionsCrystallography, X-RayHumansModels, MolecularMolecular Dynamics SimulationProtein ConformationComplementarity Determining RegionsImmunoglobulin Heavy Chainsantibody engineeringframework residuesHallmarkhumanizationmolecular dynamicsnatural killer cellsNKp30single domain antibodyVHHs

Identifiers

PMID39422475
PMCPMC11487682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.